Download PDFPDF

Electronic nicotine delivery systems and/or electronic non-nicotine delivery systems for tobacco smoking cessation or reduction: a systematic review and meta-analysis
Compose Response

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g.
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Statement of Competing Interests


  • A rapid response is a moderated but not peer reviewed online response to a published article in a BMJ journal; it will not receive a DOI and will not be indexed unless it is also republished as a Letter, Correspondence or as other content. Find out more about rapid responses.
  • We intend to post all responses which are approved by the Editor, within 14 days (BMJ Journals) or 24 hours (The BMJ), however timeframes cannot be guaranteed. Responses must comply with our requirements and should contribute substantially to the topic, but it is at our absolute discretion whether we publish a response, and we reserve the right to edit or remove responses before and after publication and also republish some or all in other BMJ publications, including third party local editions in other countries and languages
  • Our requirements are stated in our rapid response terms and conditions and must be read. These include ensuring that: i) you do not include any illustrative content including tables and graphs, ii) you do not include any information that includes specifics about any patients,iii) you do not include any original data, unless it has already been published in a peer reviewed journal and you have included a reference, iv) your response is lawful, not defamatory, original and accurate, v) you declare any competing interests, vi) you understand that your name and other personal details set out in our rapid response terms and conditions will be published with any responses we publish and vii) you understand that once a response is published, we may continue to publish your response and/or edit or remove it in the future.
  • By submitting this rapid response you are agreeing to our terms and conditions for rapid responses and understand that your personal data will be processed in accordance with those terms and our privacy notice.
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

Other responses

Jump to comment:

  • Menfil A. Orellana-Barrios, Drew Payne and Kenneth Nugent
    Published on:
  • Published on:
    Letter to the Editor
    • Menfil A. Orellana-Barrios, Physician: Internal Medicine - Cardiology University of Florida, Jacksonville
    • Other Contributors:
      • Drew Payne, Physician: Internal Medicine
      • Kenneth Nugent, Physician: Critical Care - Pulmonary

    Dear Editor:

    We commend El Dib and colleagues(1) on their extensive review effort and offer the following critiques:

    a. In their analysis regarding ENDS vs. ENNDS for smoking cessation (Figure 5)(1), the authors have chosen to compare the 6-month cessation rate for the ASCEND(2) study with the 12-month cessation rate in the ECLAT(3) study. Using equal time frames seem like it would allow a more homogenous comparison, particularly because this is available from the ECLAT publication. This does raise the bigger issue that an important conclusion in review related to e-cigarette and smoking cessation should be advocating for uniformity in outcome reporting, as has been proposed in prior publications (e.g. the Russel Standard)(4).

    b. We disagree with the author's main analysis where subjects lost to follow-up (LFU) excluded. It is incorrect to assume that the cessation rate in the LFU group is the same as the subject who actually completed the study. Regardless of this, the authors have indeed performed a "worse case" analysis but here we find discrepancy between the published cessation data from the studies and the numbers used in the analysis. Using an intention-to-treat (ITT) analysis, for instance, the ASCEND trial reported a cessation rate for ENDS of 21/289 (30/289 including non-verified) while in ECLAT this was 22/200. This is in contrast to 25/289 and 34/200, respectively, as used in the author's analysis. In the ENNDS subg...

    Show More
    Conflict of Interest:
    None declared.